Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Dexmedetomidine for Preventing Postoperative Delirium and a Risk Prediction Nomogram in Older Adults Undergoing Gastrointestinal Surgery

A legfontosabb adatok

Ki végzi
Hanoi Medical University
Hol
Vietnám1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
630 fő, tervezett
Kezdés
2026. dec. 1.
Várható befejezés
2028. ápr. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Dexmedetomidine
  • Placebo
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Életkor
60 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 60 years or older
  • Scheduled for elective gastrointestinal surgery (esophageal, gastroduodenal, small bowel, colorectal, hepatobiliary, pancreatic or splenic) under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Written informed consent from the patient, or from a legally authorized representative if the patient lacks decision-making capacity

Ki nem vehet részt

  • Expected duration of surgery < 90 minutes
  • Substance dependence or abuse, or current use of antipsychotic medication
  • Refusal by the patient or family to participate; Withdrawal criteria (after randomization): severe anesthetic or surgical complications (e.g., anaphylaxis, local anesthetic systemic toxicity, hemorrhagic shock); premature discontinuation of study drug due to adverse effects; actual surgical duration < 90 minutes; postoperative mechanical ventilation > 24 hours; re-anesthesia, spinal anesthesia or reoperation during the study period; withdrawal of consent. Patients withdrawn after starting the infusion remain in the mITT analysis
  • Severe preoperative cognitive impairment (Mini-Mental State Examination score < 14)
  • Contraindications to dexmedetomidine: known allergy, bradycardia, second- or third-degree atrioventricular block without a pacemaker, or current high-dose beta-blocker therapy
  • Hepatic failure (Child-Pugh class B or C) or end-stage renal disease requiring dialysis
  • Cancer with brain or bone metastases causing severe preoperative pain
  • Preoperative delirium
  • Communication difficulties preventing completion of study assessments

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Postoperative delirium (POD) is a common and serious complication in older adults after major gastrointestinal surgery and is associated with longer hospital stay, long-term cognitive decline and higher mortality. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist with sedative, anti-inflammatory and opioid-sparing effects, may reduce POD, but evidence in older patients undergoing gastrointestinal surgery remains inconsistent, and tools to identify which patients are at highest risk are lacking.

A teljes eredeti leírásKevesebb

The goal of this randomized, double-blind, placebo-controlled trial is to learn whether intraoperative and early postoperative dexmedetomidine prevents POD in patients aged 60 years or older undergoing elective gastrointestinal surgery under general anesthesia, and to develop a risk prediction nomogram for POD in this population. The main questions it aims to answer are:

1. Does dexmedetomidine lower the incidence of POD within 5 days after surgery compared with placebo, and is it safe? 2. How accurately can a prediction model (nomogram) built from preoperative and intraoperative factors estimate each patient's risk of POD?

Researchers will also examine how dexmedetomidine changes postoperative inflammatory and stress markers (IL-6, cortisol, CRP, NLR, SII) and their association with POD, and whether the benefit of dexmedetomidine differs across baseline-risk strata.

Participants will be randomly assigned to dexmedetomidine or placebo (0.9% saline). The blinded infusion starts 15 minutes before induction of anesthesia (dexmedetomidine 0.5 mcg/kg over 15 minutes, then 0.5 mcg/kg/h until 2 hours after surgery, or the same volume and rate of saline). Delirium will be assessed three times daily with the 3D-CAM (or CAM-ICU for patients who cannot be interviewed) from the end of surgery until postoperative day 5 or hospital discharge.

A vizsgálat 2 csoportja

  • DexmedetomidineA vizsgált kezelés

    Dexmedetomidine 4 mcg/mL (200 mcg in 50 mL 0.9% saline). Loading dose 0.5 mcg/kg infused over 15 minutes starting 15 minutes before induction of general anesthesia, followed by a maintenance infusion of 0.5 mcg/kg/h throughout surgery until 2 hours after the end of surgery.

  • Placebo (0.9% saline)Placebo, összehasonlításként

    0.9% sodium chloride 50 mL in an identical syringe, infused at the same volume, rate and duration as the dexmedetomidine arm (15-minute loading infusion before induction, then maintenance until 2 hours after the end of surgery).

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy of Dexmedetomidine in Preventing Postoperative Delirium and a Risk Prediction Nomogram in Geriatric Patients Undergoing Gastrointestinal Surgery: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial
A regiszteradat frissítve
2026. november 17.